Aurobindo Pharma establishes Malaysian subsidiary for market expansion

Aurobindo Pharma Limited, through its wholly owned subsidiary Helix Healthcare B.V., has established Aurobindo Pharma (Malaysia) SDN. BHD. The incorporation, effective September 17, 2025, aims to expand the company's pharmaceutical products business in Malaysia. This move is categorized as a related party transaction. The company confirms that neither the promoters nor the promoter group have an interest in this transaction.

The new subsidiary was incorporated with an initial share capital of RM 400,000, divided into 400,000 shares, each with a nominal value of RM 1.00. This represents a 100% subscription to the share capital in cash. As a newly incorporated entity, there is no available turnover history for the past three years.

No governmental or regulatory approvals are required for this acquisition. The disclosure aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.